<p> <b>Full Title</b><br> Protocol M24-536: An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination with Budigalimab in Advanced or Metastatic Non-Squamous NSCLC with No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations </p> <p> <b>Study Treatment</b><br> c-MET targeting antibody-drug conjugate telisotuzumab adizutecan in combination with investigational anti-PD-1 antibody budigalimab or standard chemo/immunotherapy. </p> <p> <b>Eligibility/Info</b><br> <p> Part 2: Participants must have had no prior systemic therapy for locally advanced or metastatic NSCLC. </p> </p> <p> <b>Contact</b><br> For more information about this or any other study, please contact the NYCBS Research Department:<br> Email: <a href="mailto:ResearchRecruitment@nycancer.com">ResearchRecruitment@nycancer.com</a><br> Telephone: <a href="tel:631-675-5075">631-675-5075</a><br> HALO Messaging App: "Research Team" </p> <p> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/nostrand_medical_oncology">Nostrand Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> </p>